NNRTI/PI Toxicity Switch to Darunavir Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00765154
Recruitment Status : Terminated (Difficulties in recruitment due to a change in the nature of practice.)
First Posted : October 2, 2008
Last Update Posted : November 1, 2010
Information provided by:
St Stephens Aids Trust

October 1, 2008
October 2, 2008
November 1, 2010
October 2008
July 2010   (Final data collection date for primary outcome measure)
The improvement of NNRTI/PI associated toxicity after 4 weeks of therapy with ritonavir boosted darunavir. [ Time Frame: 20 days ]
Same as current
Complete list of historical versions of study NCT00765154 on Archive Site
  • Viral load suppression below 50 copies/ml post switch [ Time Frame: between 20 and 60 days ]
  • Viral load < 400 copies/ml post switch [ Time Frame: between 20 and 60 days ]
  • Toxicity [ Time Frame: 60 days ]
  • Health related quality of life questionnaires [ Time Frame: Baseline, 20 and 60 days ]
  • Changes in fasting triglycerides post switch [ Time Frame: 20 days and 60 days ]
  • Adherence as measured via questionnaire [ Time Frame: baseline, 20 days and 60 days ]
  • Tolerability as measured by tolerability index questionnaire (HIV patients symptoms profile [ Time Frame: baseline, 20 days and 40 days ]
Same as current
Not Provided
Not Provided
NNRTI/PI Toxicity Switch to Darunavir Study
Phase IV, Two-arm, Open-label, Single-centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-infected Individuals Intolerant of Efavirenz, Ritonavir-boosted Lopinavir or Ritonavir-boosted Darunavir

The purpose of the study is to examine the effects of switching from antiretroviral combinations that includes efavirenz (Sustiva®), lopinavir/ritonavir (Kaletra®) or atazanavir/ritonavir (Reyataz®/Norvir®) in individuals experiencing side effects from one of these agents, and replacing these with a new HIV medication called Darunavir also given with ritonavir (Norvir®).

The study will primarily investigate the effect of change in medication on the subjects viral load (the levels of the HIV virus in the blood), on immunological parameters (CD4 count) and on other safety parameters (such as cholesterol) and also quality of life.

The advent of highly active antiretroviral therapy (HAART) has revolutionised the treatment of HIV disease, with both patients and physicians enjoying the marked reductions in HIV related morbidity and mortality. However, as long term therapeutic success has become a realistic goal of treatment, there are increasing reports of toxicities associated with therapy.

Indeed since the advent of HAART the major reason for change in therapy has not been a lack of efficacy associated with drug regimens but the toxicity associated with individual agents. Although the potential adverse events associated with antiretrovirals are manifold there are signature treatment-limiting toxicities associated with particular agents such as EFV and CNS/neuropsychiatric adverse events, LPV/r and gastrointestinal toxicity and ATV/r and jaundice.

A recent study performed at the Chelsea and Westminster hospital showed that 61% of regimen switches were due to toxicity and the majority of these occurred after 12 weeks of therapy.

Darunavir is a recently licensed protease inhibitor which requires ritonavir boosting.Currently DRV/r is licensed for use in treatment-experienced individuals. In triple-class experienced patients ritonavir boosted darunavir has been associated with greater viral load reductions when combined with optimized background (OB) than OB alone. A study of PI experienced patients randomized to receive Kaletra or ritonavir boosted darunavir with optimised background therapy showed significantly higher rates of virological suppression in the DRV/r arm; rates of toxicities were similar overall but less diarrhoea in the DRV/r than the Kaletra arm. Darunavir is licensed twice daily and has a high barrier to the development of resistance. DRV/r dosed at 800/100mg once daily has been compared with LPV/r in treatment-naïve subjects. DRV/r was non-inferior to LPV/r overall and performed significantly better than LPV once daily and in subjects with a high baseline viral load. DRV/r and LPV/r have also been compared head to head in 'early'treatment-experienced patients (failing first or second line therapy but LPV-naive). Overall DRV/r exhibited superiority to LPV/r with 77% and 67% achieving viral suppression to less than 50 copies/ml by intent-to-treat analysis respectively (95% confidence interval for the difference 2-17%; p <0.0001). Animal studies have shown a low risk of teratogenesis associated with DRV.

This study aims to investigate whether substitution of NNRTI/PI with ritonavir boosted darunavir leads to resolution of toxicity associated with these drugs, continued virological suppression and immunological reconstitution and whether this is associated with an improvement in quality of life.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: darunavir
    two 400mg tablets (800mg) once daily
    Other Names:
    • TMC114
    • Trade Name: Prezista
  • Drug: ritonavir
    one 100mg capsule once daily
    Other Name: Trade Name: Norvir
  • Active Comparator: Group 1
    Immediate switch from NNRTI/PI to DRV/r
    Intervention: Drug: darunavir
  • Active Comparator: Group 2
    Switch after 10 weeks from NNRTI/PI to DRV/r
    Intervention: Drug: ritonavir
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infected as documented by a licensed HIV-1 antibody ELISA test
  • Subject is currently on an antiretroviral regimen comprising of at least three licensed antiretroviral agents including efavirenz, ritonavir-boosted lopinavir or ritonavir-boosted atazanavir
  • Subject is virologically suppressed with a viral load < 50 copies/ml
  • Subject has a CD4+ count above 50 cells/ml
  • If subject is a female of childbearing potential, she must agree to use a double barrier method of contraception
  • No previous exposure to darunavir

Exclusion Criteria:

  • Pregnant or lactating women
  • Any female of childbearing potential not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs)
  • Heterosexually active male subject not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after last intake of investigational ARVs)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
SSAT 028
Not Provided
Not Provided
Dr Mark Nelson, St Stephens Aids Trust
St Stephens Aids Trust
Not Provided
Principal Investigator: Mark Nelson St Stephen's AIDS Trust
St Stephens Aids Trust
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP